Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Innovator-of-Year to AMPEL
COMPANY
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PLATFORM
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
PRODUCTS
Lupus: the right drug for the right person at the right time
On average, it takes nearly six years for people with Lupus to be diagnosed from the time they notice their first symptoms. May is Lupus Awareness month, and Dr. Amrie Grammer, co-founder of Ampel BioSolutions talks with Wendy about the state of Lupus treatments and...
Virginia Based AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
CLICK TO READ THE ARTICLE > CHARLOTTESVILLE, Va., July 9, 2019 /PRNewswire/ --Â AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic diseases, like Lupus. Revealed in the...
Alterations in Macrophage Activation May Signal a Lupus Flare
By Lara C. Pullen, PhD CLICK TO VIEW ARTICLE > Rheumatologists lack a definitive diagnostic tool to determine whether a patient has systemic lupus erythematous (SLE) and/or when a patient will experience a lupus flare. New data suggest myeloid cells in SLE patients...
The state of lupus treatments and what the future looks like.
Les Sinclair talks with Dr. Amrie Grammer about AMPEL BioSolutions, a Charlottesville Virginia company that has reengineered the gene-based technology they developed for lupus to COVID19.
Data mining could lead to therapy advances
Peter E. Lipsky, MD, Co-Founder and Chief Executive Officer of AMPEL BioSolutions, Charlottesville, VA, works to change that, and he will discuss his efforts during the Clinical Science symposium Mining Big Data for Drug Repurposing.
PARTNERS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.